Thai pre-print study on Pfizer/BioNtech injections in adolescents
in a study that should have been done during clinical trials BEFORE rolling out injections to adolescents and still hasn't been done for infants, check this study out from Thailand.
Cardiovascular Effects of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents[v1] | Preprints
pdf here: https://www.preprints.org/manuscript/202208.0151/v1/download
on page 6 of 14
"3.2. Cardiovascular findings
Cardiovascular adverse events observed during the study were tachycardia (7.64%), shortness of breath (6.64%), palpitation (4.32%), chest pain (4.32%), and hypertension (3.99%)."
on page 10 of 14
"4. Evaluation of patients developing abnormal ECG post-vaccination
After vaccination, ECG revealed that of the 301 patients, 247 (82.06%) had normal sinus rhythm, while an abnormal ECG finding was noted in 54 patients (17.94%) (Table 4). The most common abnormal ECG finding was sinus rhythm with sinus arrhythmia (7.31%), followed by sinus tachycardia (6.64%) and sinus bradycardia (1.33%). Of the two patients with abnormal rhythm, one had junctional escape rhythm, and one had ectopic atrial rhythm. Arrhythmia was observed as premature ventricular contractions in two patients (0.66%), and three (1%) had premature atrial contraction. One case (0.33%) had diffused ST elevation with PR depression."
get that? 18% of the 301 in the prospective survey of 301 adolescents in thailand had abnormal ECG readings. Sinus arrythmia was 7%.
but.. in conclusion, the paper states :
"Clinically suspected myocarditis is temporarily associated with the BNT162b2 mRNA COVID-19 vaccine in a small proportion of adolescent patients. Chest pain is an alarming symptom in patients receiving BNT162b2 mRNA COVID-19 vaccination, especially a second dose of BNT162b2. We found the risk of these symptoms to be not as low as reported elsewhere, but in all cases, symptoms were mild with full recovery within 14 days."
i did not know that you could recover from myocarditis with bed rest!
this sort of study has NOT been completed by the CDC/FDA or any other health authority like those in Canada, UK or Australia.
the BMJ accepted this on 25 May 2022 and published it on 13 July 2022
"Results 46 studies were included (14 on incidence, seven on risk factors, 11 on characteristics and short term course, three on longer term outcomes, and 21 on mechanisms). Incidence of myocarditis after mRNA vaccines was highest in male adolescents and male young adults (age 12-17 years, range 50-139 cases per million (low certainty); 18-29 years, 28-147 per million (moderate certainty))."
just around 100 per million of myocarditis (one in 10,000) amongst 12-17 year old boys with low certainty.